Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.60 |
| ▸ | GABRD | O14764 | 2/20 | 0.60 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.60 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.60 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.60 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.60 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.60 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.60 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.60 |
| ▸ | GABRE | P78334 | 2/20 | 0.60 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.60 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.60 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.60 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29604446 | 1.00 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22775321 | 1.00 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25354508 | 1.00 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15389643 | 0.84 | GABRP (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31369835 | 0.84 | GABRP (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15562032 | 0.82 | HSD17B10 (0.55) | HSD17B10SLC7A5PTGS1KDM4EUSP2 | |
| SCHEMBL15562033 | 0.82 | HSD17B10 (0.55) | HSD17B10SLC7A5PTGS1KDM4EUSP2 | |
| SCHEMBL7271055 | 0.82 | HSD17B10 (0.55) | HSD17B10SLC7A5PTGS1KDM4EUSP2 | |
| SCHEMBL31073989 | 0.82 | HSD17B10 (0.55) | HSD17B10SLC7A5PTGS1KDM4EUSP2 | |
| SCHEMBL22775485 | 0.82 | HSD17B10 (0.55) | HSD17B10SLC7A5PTGS1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC | 2024-08-29 | — | — | US | disclosed |
| CN-118201966-A | Human transferrin receptor binding antibody-peptide conjugates | 肽梦想株式会社 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-115151556-A | Human transferrin receptor binding peptides | JCR制药股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-114401732-A | CD38 binding agents and uses thereof | 克莱奥药品有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-9586988-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-8557781-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8399614-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | TNF, TNFRSF1A, CD40 | GABRP 1347/4885GABRD 1751/4885GABRA1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.